{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-027497","form_type":"8-K","ticker":"TNYA","cik":"0001858848","company_name":"Tenaya Therapeutics, Inc.","filed_at":"2023-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.317294+00:00","generated_at":"2026-06-14T03:15:03.772394+00:00","sec_items":["5.02","5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Tenaya amends severance plan: CEO gets 12-18 months salary; shareholders approve officer exculpation","bullets":["CEO Faraz Ali: non-CIC severance 12 months base; CIC severance 18 months base + 150% target bonus; COBRA up to 18 months.","Other named execs: non-CIC 9 months base; CIC 12 months base + 100% bonus; COBRA up to 12 months; equity accelerated.","Stockholders approved amendment to certificate of incorporation to limit officer personal liability for monetary damages.","Annual meeting: Directors Burroughs, Chen, Stehman-Breen elected; Deloitte & Touche ratified as independent auditor."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-027497","json":"https://secwatch.observer/filing/0000950170-23-027497.json","markdown":"https://secwatch.observer/filing/0000950170-23-027497.md","text":"https://secwatch.observer/filing/0000950170-23-027497.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858848/000095017023027497/0000950170-23-027497-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858848/000095017023027497/tnya-20230608.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T03:15:03.772394+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9d3cfe3dbb632c78af503f3ea8387f8b46828d7b","claim":"Tenaya Therapeutics, Inc.: Amendment to certificate of incorporation to adopt officer exculpation provisions under Delaware law (effective 2023-06-08).","evidence_excerpt":"On June 8, 2023, immediately following the vote on proposal 3 at the 2023 Annual Meeting of Stockholders (the “Annual Meeting”) of Tenaya Therapeutics, Inc. (the “Company”), the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to reflect recently adopted Delaware law provisions regarding officer exculpation, which amendment was effective upon filing.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858848/000095017023027497/0000950170-23-027497-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-06-08"}],"fact_type":"governance_change"},{"claim_id":"0989416b764460b9d830a46fedc051226f130010","claim":"Tenaya Therapeutics, Inc. shareholders approved Election of Class II Directors.","evidence_excerpt":"Proposal 1: Election of Class II Directors Name of Director Nominee For Withheld Broker Non-Votes Amy Burroughs, M.B.A. 56,813,999 120,571 3,354,787 Jin-Long Chen, Ph.D. 54,315,499 2,619,071 3,354,787 Catherine Stehman-Breen, M.D. 56,678,838 255,732 3,354,787 Each director nominee was duly elected to serve until the 2026 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858848/000095017023027497/0000950170-23-027497-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"9bde37b01d4657b5c862297c72064bb4acb95051","claim":"Tenaya Therapeutics, Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2023-12-31 meeting.","evidence_excerpt":"Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm For Against Abstain Broker Non-Votes 60,277,871 11,275 211 0 The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858848/000095017023027497/0000950170-23-027497-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-31"}],"fact_type":"shareholder_vote"},{"claim_id":"ce46e4548a21e2f4ec65dccb1b01175b34a99621","claim":"Tenaya Therapeutics, Inc. shareholders approved Approval of Amendment to Amended and Restated Certificate of Incorporation to Reflect Recently Adopted Delaware Law Provisions Regarding Officer Exculpation.","evidence_excerpt":"Proposal 3: Approval of Amendment to Amended and Restated Certificate of Incorporation to Reflect Recently Adopted Delaware Law Provisions Regarding Officer Exculpation For Against Abstain Broker Non-Votes 55,753,278 1,173,172 8,120 3,354,787 The stockholders approved the amendment to the Company’s Amended and Restated Certificate of Incorporation to reflect recently adopted Delaware law provisions regarding officer exculpation.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858848/000095017023027497/0000950170-23-027497-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}